Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Egfr Tyrosine Kinase Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00043823
What this trial is testing

Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Who this might be right for
Lung Cancer
M.D. Anderson Cancer Center 41
Testing effectiveness (Phase 2)WithdrawnNCT00343759
What this trial is testing

Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy

Who this might be right for
Breast Cancer
University of Pennsylvania
Early research (Phase 1)Study completedNCT02476539
What this trial is testing

Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Tianjin Hemay Pharmaceutical Co., Ltd 28
Early research (Phase 1)Study completedNCT00574366
What this trial is testing

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 14
Early research (Phase 1)Study completedNCT00072072
What this trial is testing

Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT04824079
What this trial is testing

Keynatinib in Treated Patients With NSCLC and Brain Metastases

Who this might be right for
Non-Small Cell Lung Cancer With EGFR MutationBrain Metastases
Medolution Ltd. 16
Early research (Phase 1)Study completedNCT00820417
What this trial is testing

Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib

Who this might be right for
Colorectal CancerHead and Neck CancerNon Small Cell Lung Cancer (NSCLC)
Harrison Clinical Research 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT05256290
What this trial is testing

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Who this might be right for
Non-Small Cell Lung CancerAdvanced Non-Small Cell Squamous Lung CancerMetastatic Lung Non-Small Cell Carcinoma+7 more
Black Diamond Therapeutics, Inc. 200
Testing effectiveness (Phase 2)Study completedNCT02625168
What this trial is testing

Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

Who this might be right for
Lung Cancer
The University of Hong Kong 25
Not applicableStudy completedNCT04222335
What this trial is testing

Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients

Who this might be right for
Lung Cancer, Nonsmall Cell
University Hospital, Toulouse 47
Not applicableStudy completedNCT00897663
What this trial is testing

Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies

Who this might be right for
Brain and Central Nervous System Tumors
Alliance for Clinical Trials in Oncology 56
Testing effectiveness (Phase 2)Looking for participantsNCT06922383
What this trial is testing

A Clinical Study of Arfolitixorin in Patients With mCRC

Who this might be right for
Metastatic Colorectal Cancer (mCRC)
Isofol Medical AB 90
Not applicableUnknownNCT02422628
What this trial is testing

Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC

Who this might be right for
Lung Cancer
National Taiwan University Hospital 400
Testing effectiveness (Phase 2)WithdrawnNCT01013506
What this trial is testing

Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT03983993
What this trial is testing

Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer

Who this might be right for
Advanced Microsatellite Stable Colorectal CarcinomaMetastatic Microsatellite Stable Colorectal CarcinomaMicrosatellite Stable+3 more
Emory University 26
Testing effectiveness (Phase 2)Looking for participantsNCT07326566
What this trial is testing

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Who this might be right for
Glioblastoma (GBM)Newly Diagnosed GlioblastomaGBM+4 more
Black Diamond Therapeutics, Inc. 162
Testing effectiveness (Phase 2)Looking for participantsNCT07105592
What this trial is testing

Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Fudan University 68
Early research (Phase 1)Looking for participantsNCT06905197
What this trial is testing

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Who this might be right for
Non Small Cell Lung Cancer
Dizal Pharmaceuticals 140
Post-approval studies (Phase 4)UnknownNCT04401059
What this trial is testing

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study

Who this might be right for
CarcinomaNon-Small-Cell Lung CancerAdenocarcinoma
Tian Xie 744
Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Next Page